ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2022
Artificial intelligence in lung cancer: Application and future thinking.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.Cancers · 2025Review
- Role of Artificial Intelligence in Nanomedicine and Organ-specific Therapy: An Updated Review.Current drug targets · 2025Review
- Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The availability of medical big data and the rapid development of computer software and hardware have greatly promoted the advancement of intelligent medical healthcare. Artificial intelligence (AI) has been successfully applied in many fields of medicine, especially in lung cancer. The performance of AI in some specific tasks has surpassed that of humans. Several AI software has been deeply used in clinical practice to help decision-making, which is producing a profound influence on clinicians. At present, the application of AI in the field of lung cancer mainly includes detection, segmentation, classification, prognosis prediction, efficacy evaluation, and so on. AI faces certain challenges and opportunities in the era of big data in terms of data acquisition, annotation and interpretability. Researchers have conducted deep and extensive studies using AI in the field of lung cancer, and AI is expected to become a powerful assistant in the prevention and treatment of lung cancer. AI is bringing an unprecedented revolution to radiologists, but the role of radiologists is crucial in the development of AI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.